NRXP NRX Pharmaceuticals, Inc.

Nasdaq nrxpharma.com


$ 3.08 $ -0.07 (-2.24 %)    

Tuesday, 14-Oct-2025 18:53:12 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 3.05
$ 3.13
$ 3.06 x 2
$ 3.39 x 48
$ 2.95 - $ 3.18
$ 1.10 - $ 6.01
395,039
na
60.1M
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-18-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-14-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 08-14-2023 06-30-2023 10-Q
9 05-15-2023 03-31-2023 10-Q
10 03-31-2023 12-31-2022 10-K
11 11-14-2022 09-30-2022 10-Q
12 08-15-2022 06-30-2022 10-Q
13 05-16-2022 03-31-2022 10-Q
14 03-31-2022 12-31-2021 10-K
15 11-15-2021 09-30-2021 10-Q
16 08-16-2021 06-30-2021 10-Q
17 05-21-2021 03-31-2021 10-Q
18 04-01-2021 12-31-2020 10-K
19 11-16-2020 09-30-2020 10-Q
20 08-14-2020 06-30-2020 10-Q
21 05-15-2020 03-31-2020 10-Q
22 03-30-2020 12-31-2019 10-K
23 11-14-2019 09-30-2019 10-Q
24 08-14-2019 06-30-2019 10-Q
25 05-15-2019 03-31-2019 10-Q
26 03-15-2019 12-31-2018 10-K
27 11-08-2018 09-30-2018 10-Q
28 08-08-2018 06-30-2018 10-Q
29 05-15-2018 03-31-2018 10-Q
30 03-23-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-nrx-pharmaceuticals-maintains-40-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $4...

 d-boral-capital-maintains-buy-on-nrx-pharmaceuticals-maintains-34-price-target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ: NRXP) with a Buy and maintains $34 price target.

 nrx-pharmaceuticals-re-files-its-abbreviated-new-drug-application-with-fda-for-ketafree

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the re-filing of its Abbr...

 d-boral-capital-maintains-buy-on-nrx-pharmaceuticals-maintains-34-price-target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ: NRXP) with a Buy and maintains $34 price target.

 nrx-pharmaceuticals-announces-fda-has-granted-suitability-petition-for-its-planned-preservative-free-ketamine-product-ketafree

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, announced that it was notified yesterday b...

 d-boral-capital-maintains-buy-on-nrx-pharmaceuticals-maintains-34-price-target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.

 hc-wainwright--co-assumes-nrx-pharmaceuticals-at-buy-announces-price-target-of-40

HC Wainwright & Co. analyst Patrick R. Trucchio assumes NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy rating and announce...

 fda-grants-fast-track-to-nrxs-nrx-100-for-suicidal-depression-expanded-access-now-available-for-eligible-patients

US Food and Drug Administration (FDA) has granted Fast Track designation for NRX-100 in the treatment of suicidal ideation in p...

 d-boral-capital-maintains-buy-on-nrx-pharmaceuticals-raises-price-target-to-34

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target fr...

 d-boral-capital-maintains-buy-on-nrx-pharmaceuticals-maintains-31-price-target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $31 price target.

 nrx-pharmaceuticals-q2-eps-098-misses-020-estimate

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of...

 nrx-pharmaceuticals-to-release-q2-2025-financial-results-on-august-19-2025-and-host-conference-call-at-800am-et-on-august-20-2025

Conference Call 8:00am ET, Wednesday August 20, 2025WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (...

 d-boral-capital-maintains-buy-on-nrx-pharmaceuticals-maintains-31-price-target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $31 price target.

 d-boral-capital-maintains-buy-on-nrx-pharmaceuticals-maintains-31-price-target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $31 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION